Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study
Marco Galluzzo(University of Rome Tor Vergata), Pietro Rubegni(University of Siena), Andrea Chiricozzi(Università Cattolica del Sacro Cuore), Emanuele Trovato(University of Siena), Emanuele Cozzani(Ospedale Policlinico San Martino), Claudia Paganini(University of Rome Tor Vergata), Laura Vellucci(University of Rome Tor Vergata), Laura Lazzeri(University of Siena), Nicoletta Bernardini(Sapienza University of Rome), Lucia Di Nardo(Università Cattolica del Sacro Cuore), Marina Talamonti(NorthShore University HealthSystem), Martina Burlando(Martin University), Concetta Potenza(Danieli (Italy)), Riccardo Balestri(Ospedale Santa Chiara), Laura Atzori(University of Cagliari), Giacomo Caldarola(Università Cattolica del Sacro Cuore), Cristina Mugheddu(University of Cagliari), Clara De Simone(IRCCS San Camillo Hospital), Maria Antonia Montesu(University of Sassari), Gabriele Biondi(University of Sassari), Giulia Rech(Ospedale Santa Chiara), Filomena Russo(University of Siena)
Cited by 7
Related Papers
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
|Clinical Reviews in Allergy & Immunology|2018|738
Scanning the Immunopathogenesis of Psoriasis
|International Journal of Molecular Sciences|2018|317
Understanding the Molecular Genetics of Basal Cell Carcinoma
|International Journal of Molecular Sciences|2017|243
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
|British Journal of Dermatology|2020|175
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
|Journal of Allergy and Clinical Immunology|2020|160